MTEM vs. BOLT, SABS, WVE, COGT, BMY, SNY, AMGN, VRTX, REGN, and GILD
Should you be buying Molecular Templates stock or one of its competitors? The main competitors of Molecular Templates include Bolt Biotherapeutics (BOLT), SAB Biotherapeutics (SABS), Wave Life Sciences (WVE), Cogent Biosciences (COGT), Bristol-Myers Squibb (BMY), Sanofi (SNY), Amgen (AMGN), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), and Gilead Sciences (GILD). These companies are all part of the "medical" sector.
Molecular Templates (NASDAQ:MTEM) and Bolt Biotherapeutics (NASDAQ:BOLT) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, valuation, earnings, dividends, community ranking, analyst recommendations and risk.
Molecular Templates received 262 more outperform votes than Bolt Biotherapeutics when rated by MarketBeat users. Likewise, 67.32% of users gave Molecular Templates an outperform vote while only 65.57% of users gave Bolt Biotherapeutics an outperform vote.
Bolt Biotherapeutics has a consensus price target of $3.50, indicating a potential upside of 366.67%. Given Bolt Biotherapeutics' higher possible upside, analysts plainly believe Bolt Biotherapeutics is more favorable than Molecular Templates.
In the previous week, Bolt Biotherapeutics had 13 more articles in the media than Molecular Templates. MarketBeat recorded 14 mentions for Bolt Biotherapeutics and 1 mentions for Molecular Templates. Molecular Templates' average media sentiment score of 1.87 beat Bolt Biotherapeutics' score of 0.10 indicating that Molecular Templates is being referred to more favorably in the media.
Molecular Templates has a beta of 1.19, meaning that its share price is 19% more volatile than the S&P 500. Comparatively, Bolt Biotherapeutics has a beta of 0.94, meaning that its share price is 6% less volatile than the S&P 500.
95.5% of Molecular Templates shares are held by institutional investors. Comparatively, 86.7% of Bolt Biotherapeutics shares are held by institutional investors. 18.7% of Molecular Templates shares are held by company insiders. Comparatively, 30.9% of Bolt Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Molecular Templates has a net margin of -57.92% compared to Bolt Biotherapeutics' net margin of -556.59%. Bolt Biotherapeutics' return on equity of -51.74% beat Molecular Templates' return on equity.
Molecular Templates has higher revenue and earnings than Bolt Biotherapeutics. Bolt Biotherapeutics is trading at a lower price-to-earnings ratio than Molecular Templates, indicating that it is currently the more affordable of the two stocks.
Summary
Molecular Templates beats Bolt Biotherapeutics on 9 of the 16 factors compared between the two stocks.
Get Molecular Templates News Delivered to You Automatically
Sign up to receive the latest news and ratings for MTEM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MTEM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Molecular Templates Competitors List
Related Companies and Tools
Free MTEM Stock Alerts